Alba Del Rio-Gonzalez
Research Subjects
Alba Del Rio-Gonzalez has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Arnedo-Pena
Centro de Salud Pública, Castelló de la Plana, Spain; CIBER de Epidemiologia y Salud Pública (CI-BERESP), Madrid; and Departamento de Ciencias de la Salud, Universidad Pública de Navarra, Spain;, Spain
1 shared publication - Carmen Domènech-León
Department of Medicine, Universidad CEU Cardenal Herrera, 12006 Castelló de la Plana, Spain
1 shared publication - Cristina Notari-Rodriguez
Emergency Service University Hospital de la Plana, 12540 Vila-real, Spain, Spain
1 shared publication - Diego Sala-Trull
Emergency Service Department, University Hospital de la Plana, 12540 Vila-Real, Spain
1 shared publication - Gema Badenes-Marques
Emergency Service Department, University Hospital de la Plana, 12540 Vila-Real, Spain
1 shared publication - Isabel Aleixandre-Gorriz
Clinical Analysis Service Department, University Hospital de la Plana, 12540 Vila-Real, Spain
1 shared publication
Latest Publications
- Open Access
- 4 November 2025
- Published by MDPI AG in Preprints.org
SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
Evaluation of vaccine effectiveness (VE) was essential to implement strategies of prevention, and our objective was estimated the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines to prevent SARS-CoV-2 infection. We performed a population-based prospective cohort study in the Borriana COVID-19 cohort (Valencia Community, Spain) during the period 2021-2023, with two approaches, considering firstly, all cases occurred after SARS-CoV-2 vaccine campaign started in January 2021, and then secondly, only symptomatic cases. Multivariable robust Poisson regression models were employed. Results: In first approach, of 301 participants, 285 were vaccinated, 228 with only SARS-CoV-2 mRNA vaccines, and 57 with mRNA vaccine and other vaccines. A total of 226 cases occurred with 75 non-cases. Adjusted VE for 3 doses of vaccine received was 37% (95% Confidence interval [CI] 22%-49%). The second approach, with 153 symptomatic cases, excluding 73 asymptomatic cases, adjusted VE for 3 doses of vaccine received was 50% (95% CI 33%-63%). While one or two doses of vaccines presented a low VE with insufficient to protect against infection, 3 doses of vaccine reached modest and significant protection. Exclusion of asymptomatic cases improved the VE estimation. Conclusion: Development of new vaccines is needed to improve control and prevention strategies against SARS-CoV-2.
- 4 November 2025
- Published by MDPI AG in Preprints.org
Open AccessSARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
Evaluation of vaccine effectiveness (VE) was essential to implement strategies of prevention, and our objective was estimated the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines to prevent SARS-CoV-2 infection. We performed a population-based prospective cohort study in the Borriana COVID-19 cohort (Valencia Community, Spain) during the period 2021-2023, with two approaches, considering firstly, all cases occurred after SARS-CoV-2 vaccine campaign started in January 2021, and then secondly, only symptomatic cases. Multivariable robust Poisson regression models were employed. Results: In first approach, of 301 participants, 285 were vaccinated, 228 with only SARS-CoV-2 mRNA vaccines, and 57 with mRNA vaccine and other vaccines. A total of 226 cases occurred with 75 non-cases. Adjusted VE for 3 doses of vaccine received was 37% (95% Confidence interval [CI] 22%-49%). The second approach, with 153 symptomatic cases, excluding 73 asymptomatic cases, adjusted VE for 3 doses of vaccine received was 50% (95% CI 33%-63%). While one or two doses of vaccines presented a low VE with insufficient to protect against infection, 3 doses of vaccine reached modest and significant protection. Exclusion of asymptomatic cases improved the VE estimation. Conclusion: Development of new vaccines is needed to improve control and prevention strategies against SARS-CoV-2.